Compare LAC & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAC | ZVRA |
|---|---|---|
| Founded | 2023 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 686.2M | 664.7M |
| IPO Year | 2023 | 2015 |
| Metric | LAC | ZVRA |
|---|---|---|
| Price | $1.67 | $11.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | $5.07 | ★ $25.25 |
| AVG Volume (30 Days) | ★ 7.5M | 875.2K |
| Earning Date | 11-13-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 1.03 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | N/A | $43.42 |
| Revenue Next Year | N/A | $16.20 |
| P/E Ratio | ★ N/A | $11.58 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $1.78 | $8.01 |
| 52 Week High | $6.96 | $15.04 |
| Indicator | LAC | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 29.45 | 59.95 |
| Support Level | N/A | $9.58 |
| Resistance Level | $2.22 | $12.19 |
| Average True Range (ATR) | 0.13 | 0.55 |
| MACD | 0.00 | 0.24 |
| Stochastic Oscillator | 1.85 | 87.41 |
Lithium Americas Corp is a Canadian-based resource and materials company focused on developing, building and operating lithium deposits and chemical processing facilities. The company also holds investments in Green Technology Metals Limited (GT1) and Ascend Elements, Inc. (Ascend Elements), and exploration properties in the U.S. and Canada. The company's flagship asset is Thacker Pass, a sedimentary-based lithium deposit located in the McDermitt Caldera in Humboldt County, in northern Nevada (Thacker Pass or the Project). The company operates in only one operating segment and one geographical segment.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.